The Evolving Role of Stem Cell Transplants in Lymphomas

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 5, 2012, Pages 660-673

  Jantunen, Esa ^a   Sureda, Anna ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Allogeneic stem cell transplantation; Autologous stem cell transplantation; Hodgkin's lymphoma; Non Hodgkin lymphoma; Nonrelapse mortality; Outcome

Indexed keywords

ALLOTRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER TRANSPLANTATION; CLINICAL EFFECTIVENESS; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMA; MANTLE CELL LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; REVIEW; TREATMENT INDICATION;

DISEASE-FREE SURVIVAL; EUROPE; HUMANS; IMMUNOTHERAPY; LYMPHOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; REMISSION INDUCTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84859852171     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.09.009     Document Type: Review

References (119)

1. Gratwohl A., Baldomero H., Schwendener A., et al. The EBMT activity survey 2008: impact of team size, team density and new trends. Bone Marrow Transplant 2011, 46:174-191.
2. Pfreundschuh M., Truemper L., österborg A., et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7:379-391.
3. Coiffier B., Lepage E., Briere J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
4. Hiddemann W., Kneba M., Dreyling M., et al. Frontline therapy with rituximab added to combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study by the German Low-Grade Lymphoma Study Group. Blood 2005, 106:3725-3732.
5. van Oers M., Klasa R., Marcus R.E., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006, 108:3295-3301.
6. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphoma: results of the NHL-B1 trial of DSHNHL. Blood 2004, 104:626-633.
7. Pfreundschuh M., Trumper L., Kloess M., et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004, 104:634-641.
8. Romaguera J.E., Fayad L., Rodriquez M.A., et al. High rate of durable remission after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013-7023.
9. Ljungman P., Bregni M., Brune M., et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe. Bone Marrow Transplant 2010, 45:219-234. for the European Group for Blood and Marrow Transplantation.
10. Appelbaum F.R. Hematopoietic cell transplantation for non-Hodgkin's lymphoma: yesterday, today, and tomorrow. J Clin Oncol 2008, 26:2927-2929.
11. Greb A., Bohlius J., Schiefer D., et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev 2008, CD004224.
12. Milpied N., Le Gouill S., Lamy T., et al. No benefit of first line rituximab (R)-high-dose therapy (R-HDT) over R-CHOP-14 for young adults with diffuse large B-cell lymphoma. Preliminary results of the GOELAMS 075 prospective multicentre randomized trial. Blood 2010, 116:301-302. (abstr. 685).
13. Schmitz N., Nickelsen M., Ziepert M., et al. Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: final results of the randomized Mega-CHOEP-trial of the German High-Grade non-Hodgkin Lymphoma Study Group (DSHNHL). Ann Oncol 2011, 22(Suppl. 4). iv 106-107.
14. Vitolo A., Chiappella A., Brusamolino E., et al. A randomized multicentre phase III study for first line treatment of young patients with high risk (AAIPI 2-3) diffuse large B-cell lymphoma: Rituximab® plus dose-dense chemotherapy CHOP-14/MegaCHOP-14 with or without intensified high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Results from DLCL04 trial of the Italian Lymphoma Foundation (FIL). Ann Oncol 2011, 22(Suppl. 4). iv 106.
15. Nyman H., Jantunen E., Juvonen E., et al. Impact of germinal center phenotype on overall and failure-free survival after high-dose chemotherapy and auto-SCT in primary diffuse large B-cell lymphoma. Bone Marrow Transplant 2008, 42:93-98.
16. Kewalramani T., Zelenetz A.D., Hedrick E.E., et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000, 96:2399-2404.
17. Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared to salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphomas. N Engl J Med 1995, 333:1540-1545.
18. Martin A., Conde E., Arnan M., et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008, 93:1829-1836.
19. Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010, 28:4184-4190.
20. Shimoni A., Avivi I., Rowe J.M., et al. A multi-center prospective randomized study comparing ibritumomab tiuxetan (Zevalin) and BEAM chemotherapy (Z-BEAM) vs. BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma: possible advantege of Z-BEAM in low risk patients. Blood 2010, 116:302. (abstr. 686).
21. Bishop M.R., Dean R.M., Steinberg S.M., et al. Clinical evidence of a graft-versus-lymphoma effect against relapsed diffuse large B-cell lymphoma after allogeneic hematopoietic stem cell transplantation. Ann Oncol 2008, 19:1935-1940.
22. Rezvani A.R., Norasetthada L., Gooley T., et al. Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma. Br J Haematol 2008, 143:395-403.
23. Sirvent A., Dhedin N., Michallet M., et al. Low non-relapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant 2010, 16:78-85.
24. Thomson K.J., Morris E.C., Bloor A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:426-432.
25. van Kampen R.J.W., Canals C., Schouten H., et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after autologous stem cell transplantation: an analysis of the Europen Group for Blood and Marrow Transplantation registry. J Clin Oncol 2011, 29:1342-1348.
26. Avivi I., Canals C., Luan J.J., et al. Matched unrelated donor transplantation is curative in selected patients with diffuse large B cell lymphoma: a report of the Lymphoma Working Party (LWP) of the European Group for Blood and Marrow Transplantation (EBMT). Blood 2010, 116:164-165. (abstr. 363).
27. Salles G., Seymour J.F., Offner F., et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomized controlled trial. Lancet 2011, 377:42-51.
28. Montoto S., Davies A.J., Matthews J., et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 2007, 25:2436-2443.
29. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-grade Lymphoma Study Group. Blood 2004, 104:2667-2674.
30. Deconinck E., Foussard C., Milpied N., et al. High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS. Blood 2005, 105:3817-3823.
31. Sebban C., Mounier N., Brousse N., et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006, 108:2540-2544.
32. Gyan E., Foussard C., Bertrand P., et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood 2009, 113:995-1001.
33. Ladetto M., De Marco F., Benedetti F., et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control in R-HDS does not translate into an overall survival advantage. Blood 2008, 111:4004-4013.
34. Schouten H.C., Qian W., Kvaloy S., et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003, 21:3919-3927.
35. Brice P., Simon D., Bouabdallah R., et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 2000, 11:1585-1590.
36. Rohatiner A.Z., Nadler L., Davies A.J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007, 25:2554-2559.
37. Pettengell R., Schmitz N., Gisselbrecht C., et al. Rituximab purging and maintenance improves progression free survival but not overall survival in patients with relapsed or resistant follicular lymphoma prior to receiving autologous transplant. Blood 2010, 116:1647-1648. (abstr. 3567).
38. Le Gouill S., De Guibert S., Planche L., et al. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in GELA/GOELAMS FL2000 study. Haematologica 2011, 98:1128-1135.
39. Decaudin D., Mounier N., Tilly H., et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z-BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma 2011, 11:212-218.
40. Hamadani M., Benson D.M., Lin T.S., et al. High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. Eur J Haematol 2008, 81:425-431.
41. Williams C.D., Harrison C.N., Lister T.A., et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant registry. J Clin Oncol 2001, 19:727-735.
42. van Besien K., Loberiza F.R., Bajorunaite R., et al. Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. Blood 2003, 102:3521-3529.
43. Morris E., Thomson K., Craddock C., et al. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 2004, 104:3865-3871.
44. Khouri I.F., McLaughlin P., Saliba R.M., et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood 2008, 111:5530-5536.
45. Thomson K.J., Morris E.C., Milligan D., et al. T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma. J Clin Oncol 2010, 28:3695-3700.
46. Delgado J., Canals C., Attal M., et al. The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma. Leukemia 2011, 25:551-555.
47. Avivi I., Montoto S., Canals C., et al. Matched unrelated donor stem cell transplant in 131 patients with follicular lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Br J Haematol 2009, 147:719-728.
48. Shimoni A., Zwas S.T., Oksman Y., et al. Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation in patients with chemorefractory non-Hodgkin's lymphoma. Bone Marrow Transplant 2008, 41:355-361.
49. Bethke W.A., Lange T., Meisner C., et al. Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase II study. Blood 2010, 116:1795-1802.
50. Robinson SP, Canals C, Luan JJ, et al. Reduced intensity allogeneic versus autologous stem cell transplantation as a first transplant strategy in the treatment of relapsed follicular lymphoma: a comparative analysis from the Lymphoma Working Party of the EBMT. Submitted 2011.
51. Gratwohl A., Stern M., Brand R., et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer 2009, 115:4715-4726.
52. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response rate and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984-1992.
53. Ghielmini M., Zucca E. How I treat mantle cell lymphoma. Blood 2009, 114:1469-1476.
54. Khouri I., Romaguera J., Kantarjian H., et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809.
55. Gianni A.M., Magni M., Martelli M., et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab purged stem cell autografting (HDS-regimen). Blood 2003, 102:749-755.
56. Vigoroux S., Gaillard F., Moreau P., Harousseau J.L., Milpied N. High-dose therapy with autologous stem cell transplantation in first response in mantle cell lymphoma. Haematologica 2005, 90:1580-1582.
57. Dreger P., Rieger M., Seyfarth B., et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects of molecular response and clinical outcome. Haematologica 2007, 92:42-49.
58. Geisler C., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693. for the Nordic Lymphoma Group.
59. Vandenberghe E., Ruiz de Elvira C., Loberiza F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Marrow Transplantation and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120:783-800.
60. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
61. Geisler C.H., Kolstad A., Laurell A., et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010, 115:1530-1533.
62. Andersen N.S., Pedersen L.B., Laurell A., et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009, 27:4365-4370.
63. Hermine O., Hoster E., Walewski J., et al. Alternating courses of 3 × CHOP and 3 × DHAP plus rituximab followed by a high-dose AraC containing myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network. Blood 2010, 116:54. (abstr. 110).
64. Rubio M.T., Boumendil A., Luan J.J., et al. Is there still place for total body irradiation (TBI) in the conditioning regimen of autologous stem cell transplantation in mantle cell lymphoma? A retrospective study from the Lymphoma Working Party of the EBMT. Blood 2010, 116:303. (abstr. 688).
65. Peterlin P., Leux C., Gastinne T., et al. Autologous stem cell transplantation in mantle cell lymphoma: total body irradiation (TBI) plus cyclophosphamide (or melphalan) is not superior to BEAM: single institutional experience. Blood 2010, 116:1466. (abstr. 3563).
66. Pott C., Hoster E., Delfau-Larue M.H., et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immonochemotherapy: a European MCL intergroup study. Blood 2010, 115:3215-3223.
67. Kolstad A., Laurell A., Andersen N.S., et al. 90Y-ibritumomab tiuxetan (Zevalin®)-BEAM/C with autologous stem cell support as frontline therapy for advanced mantle cell lymphoma. Preliminary results from the third Nordic phase II study (MCL3). Blood 2009, 114:384. (abstr. 937).
68. Martin P., Chadburn A., Christos P., et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008, 19:1327-1330.
69. Jantunen E., Canals C., Attal M., et al. Autologous stem cell transplantation in patients with mantle cell lymphoma beyond 65 years of age: a study from the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 2011 Apr 5, (Epub ahead of print).
70. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004, 104:3535-3542.
71. Russell N.H., Byrne J.L., Faukner R.D., Gilyead M., Das-Gupta E.P., Haynes A.P. Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation. Bone Marrow Transplant 2005, 36:437-441.
72. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
73. Cook G., Smith G.M., Kirkland K., et al. Outcome following reduced intensity allogeneic stem cell transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2010, 16:1419-1427.
74. Robinson S.P., Luan J.J., Canals C., et al. Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma: the EBMT experience. Ann Oncol 2011, 22(Suppl. 4). iv 94-95.
75. Schmitz N., Truemper L., Ziepert M., et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-grade Non-Hodgkin Lymphoma Study Group. Blood 2010, 116:3418-3425.
76. Gale J., Simmonds P.D., Mead G.M., Sweetenham J., Wright D.H. Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 2000, 18:795-803.
77. Al-Toma A., Verbeek W.H., Hadithi M., von Blomberg B.H., Mulder C.J. Survival in refractory celiac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single centre experience. Gut 2007, 56:1373-1378.
78. d'Amore F., Jantunen E., Relander T. Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how?. Curr Hematol Malign Rep 2009, 4:236-244.
79. Corradini P., Tarella C., Zallio F., et al. Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006, 20:1533-1538.
80. Reimer P., Rudiger T., Geissinger E., et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol 2009, 27:106-113.
81. d'Amore F., Relander T., Lauritzen G.F., et al. Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remission in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)-overall and subtype-specific results of a phase II study from the Nordic Lymphoma Group. Haematologica 2009, 94:437. (abstr.).
82. Relander T., Lauritzsen G., Jantunen E., et al. Favourable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and autologous stem cell transplantation (ASCT): a prospective study by the Nordic Lymphoma Group (NLG-T-01). Blood 2010, 116:1467. (abstr. 3566).
83. Sibon D., Fournier M., Briere J., et al. Prognostic factors and long-term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2010, 116:146-147. (abstr. 322).
84. Rodriquez J., Conde E., Gutierrez A., et al. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GEL-TAMO experience. Eur J Haematol 2007, 78:290-296.
85. Lauritzen G.F., Relander T., Jantunen E., et al. CHOEP-14 and autologous stem cell transplantation (ASCT) in angioimmunoblastic T-cell lymphoma: prospective study by the Nordic Lymphoma Group (NLG-T-01). Ann Oncol 2011, 22(Suppl. 4). iv 126.
86. Kyriakou C., Canals C., Goldstone A., et al. High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of outcome. J Clin Oncol 2008, 26:218-224.
87. Jantunen E., Juvonen E., Wiklund T., Putkonen M., Nousiainen T. High-dose therapy supported by autologous stem cell transplantation in patients with enteropathy-associated T-cell lymphoma. Leuk Lymphoma 2003, 44:2163-2164.
88. Jantunen E., Relander T., Lauritzsen G., et al. Intensive induction followed by autologous stem cell transplantation (ASCT) in patients with enteropathy-associated T-cell lymphoma: a prospective study by the Nordic Lymphoma Group (NLG-T-01). Blood 2010, 116:1467. (abstr. 3565).
89. Sieniawski M., Angamuthu N., Boyd K., et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood 2010, 115:3664-3670.
90. Utsumoniya A., Miyazaki Y., Takatsuka Y., et al. Improved outcome of adult T cell leukaemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 27:15-20.
91. Corradini P., Dodero A., Zallio F., et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced intensity conditioning followed by allogeneic transplantation of hematopoietic cells. J Clin Oncol 2004, 22:2171-2176.
92. Le Gouill S., Milpied N., Buzyn A., et al. Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. J Clin Oncol 2008, 26:2264-2271.
93. Kyriakou C., Canals C., Finke J., et al. Allogeneic stem cell transplantation is able to induce remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2009, 27:3951-3958.
94. Hishizawa M., Kanda J., Utsunomiya A., et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study. Blood 2010, 116:1369-1376.
95. Duarte R.F., Canals C., Onida F., et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sezary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010, 28:4492-4499.
96. Linch D.C., Winfield D., Goldstone A.H., et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993, 341:1051-1054.
97. Schmitz N., Pfistner B., Sextro M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease. Lancet 2002, 359:2065-2071.
98. Josting A., Rudolph C., Mapara M., et al. Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 2005, 16:116-123.
99. Josting A., Mueller H., Borchmann P., et al. Dose intensity of chemotherapy in patients with relapsed Hodgkin's lymphoma. J Clin Oncol 2010, 28:5074-5080.
100. Brice P., Bouabdallah R., Moreau P., et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Bone Marrow Transplant 1997, 20:21-26.
101. Josting A., Engert A., Diehl V., Canellos G.P. Prognostic factors and treatment outcome in patients with primary progressive and relapsed Hodgkin's disease. Ann Oncol 2002, 13(Suppl. 1):112-116.
102. Moskowitz C.H., Nimer S.D., Zelenetz A.D., et al. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97:616-623.
103. Tarella C., Cuttica A., Vitolo U., et al. High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: a multicenter study of the Intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence. Cancer 2003, 97:2748-2759.
104. Schot B.W., Zijlstra J.M., Sluiter W.J., et al. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurrent lymphoma. Blood 2007, 109:486-491.
105. Jabbour E., Hosing C., Ayers G., et al. Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 2007, 109:2481-2489.
106. Gajewski J.L., Philips G.L., Sobocinski K.A., et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 1996, 14:572-578.
107. Milpied N., Fielding A.K., Perace R.M., Ernst P., Goldstone A.H. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. J Clin Oncol 1996, 14:1291-1296.
108. Sureda A., Robinson S., Canals C., et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2008, 26:455-462.
109. Robinson S.P., Sureda A., Canals C., et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting outcome. Haematologica 2009, 94:230-238.
110. Anderlini P., Saliba R., Acholonu S., et al. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 2005, 35:943-951.
111. Alvarez I., Sureda A., Caballero M.D., et al. Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 2006, 12:172-183.
112. Peggs K.S., Kayani I., Edwards N., et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin's lymphoma. J Clin Oncol 2011, 29:971-978.
113. Nagler A., Slavin S., Varadi G., Naparstek E., Samuel S., Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000, 25:1021-1028.
114. Calandra G., McCarty J., McGuirk J., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
115. d'Addio A., Curti A., Worel N., et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2011, 46:356-363.
116. Jantunen E., Kuittinen T., Mahlamäki E., Pyörälä M., Mäntymaa P., Nousiainen T. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience. Eur J Haematol 2011, 86:299-304.
117. Yunes A., Bartlett N.L., Leonard J.P., et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010, 363:1812-1821.
118. Gooley T.A., Chien J.W., Pergam S.A., et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010, 363:2091-2101.
119. Gratwohl A., Brand R., Niederwieser D., et al. Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation. J Clin Oncol 2011, 29:1980-1986.